Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PARAPLATIN vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carboplatin, a platinum-based alkylating agent, forms interstrand and intrastrand DNA cross-links by binding to DNA guanine bases, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Ovarian carcinoma: treatment of advanced ovarian carcinoma in combination with other chemotherapy agents,Non-small cell lung cancer: treatment of advanced NSCLC in combination with other agents,Off-label: head and neck cancer, bladder cancer, endometrial cancer, testicular cancer, small cell lung cancer
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
360 mg/m2 IV every 3 weeks or area under the curve (AUC) 4-6 mg/m L/min IV every 3-4 weeks using Calvert formula.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life: 2.6-5.1 hours (initial phase), 22-52 hours (terminal phase) for total platinum; 1.3-2.1 hours for ultrafilterable platinum. Clinically, the terminal half-life reflects slow release of protein-bound platinum.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Carboplatin is minimally metabolized in the liver; the majority of the drug is eliminated unchanged by renal excretion via glomerular filtration and tubular secretion. It is not extensively metabolized by cytochrome P450 enzymes.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal excretion: ~70-90% of platinum is excreted in urine within 24 hours, primarily as unchanged drug. Fecal excretion: <6%. Biliary excretion: minimal.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Protein binding: ~90% of circulating platinum is irreversibly bound to plasma proteins (primarily albumin) within 4 hours of infusion; only free drug is pharmacologically active.
Approximately 85-90% bound to serum albumin.
Volume of distribution: 10-16 L/kg (total platinum), 0.3-0.5 L/kg (ultrafilterable platinum). High Vd indicates extensive tissue distribution, including into tumors.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
IV administration only; oral bioavailability is negligible (<2%) due to poor absorption and rapid degradation in GI tract.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
Creatinine clearance (Cr Cl) 41-59 m L/min: 250 mg/m2 IV every 3-4 weeks; Cr Cl 16-40 m L/min: 200 mg/m2 IV every 3-4 weeks; Cr Cl <15 m L/min: not recommended. Alternatively, AUC dosing: Cr Cl 41-59 m L/min: AUC 4; Cr Cl 16-40 m L/min: AUC 3; Cr Cl <15 m L/min: not recommended.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
No specific Child-Pugh based modifications established; use caution in severe hepatic impairment; baseline dose reduction to 200-250 mg/m2 recommended in patients with bilirubin >1.5 mg/d L or transaminases >2x upper limit of normal.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
300-600 mg/m2 IV every 3-4 weeks; alternatively, 90-150 mg/m2 IV weekly for 4 weeks then 2-week rest. Adjust for renal function using Calvert formula with pediatric GFR estimation.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment solely for age; calculate dose based on GFR using Calvert formula; monitor for increased myelosuppression and neurotoxicity; consider starting at lower AUC (4-5) in patients with decreased renal function.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Carboplatin should be administered under the supervision of a physician experienced in cancer chemotherapy. Myelosuppression is dose-dependent and may be severe, with bone marrow suppression requiring close monitoring. Anaphylactic reactions have been reported and may be fatal. Use caution in patients with prior hypersensitivity to platinum compounds.
None.
Bone marrow suppression (thrombocytopenia, neutropenia, anemia) is dose-limiting; monitor blood counts. Nephrotoxicity may occur, especially in patients with renal impairment; assess renal function before and during therapy. Neurotoxicity (peripheral neuropathy) is less common than with cisplatin but may occur. Ototoxicity risk increases with higher cumulative doses. Anaphylactic reactions can occur. Hemolytic uremic syndrome has been reported. Use caution in patients with prior platinum hypersensitivity.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
History of severe allergic reactions to carboplatin or other platinum-containing compounds; severe bone marrow suppression; significant bleeding disorders; severe renal impairment (creatinine clearance < 30 m L/min) unless benefit outweighs risk.
Hypersensitivity to AURLUMYN or any of its components.
No significant food interactions. Avoid grapefruit and grapefruit juice if patient is on concurrent CYP3A4-metabolized drugs (e.g., aprepitant).
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Pregnancy Category D. First trimester: High risk of teratogenicity; embryotoxicity, fetal malformations (neural tube, skeletal, cardiovascular). Second and third trimesters: Risk of fetal growth restriction, prematurity, low birth weight, neonatal myelosuppression, and long-term developmental effects.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Excreted in human milk; no M/P ratio available. Risk of severe neonatal adverse effects; contraindicated during breastfeeding. Discontinue drug or nursing.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No established specific dose adjustments in pregnancy; physiological changes (increased plasma volume, enhanced renal clearance) may reduce systemic exposure; however, safety data insufficient. Use Calvert formula based on renal function; monitor for toxicity and adjust as needed.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Paraplatin (carboplatin) dosing is based on renal function using Calvert formula to calculate AUC. Dose adjustments required for Cr Cl <60 m L/min. Administer IV infusion over 15-60 minutes. Hypersensitivity reactions may occur after multiple cycles; premedicate with antihistamines and corticosteroids if prior reaction. Monitor CBC weekly during treatment. Emetogenic potential: moderate-high; use antiemetic prophylaxis. Avoid concurrent nephrotoxic drugs. Myelosuppression (especially thrombocytopenia) is dose-limiting.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
This drug may lower your blood cell counts; report any signs of infection (fever, chills), easy bruising or bleeding, or unusual tiredness.,You may experience nausea or vomiting; take anti-nausea medications as prescribed.,Avoid live vaccines during treatment and for 6 months after.,Tell your doctor if you have had an allergic reaction to platinum-based drugs.,Use effective contraception during and for 6 months after treatment; do not breastfeed.,Drink plenty of fluids to stay hydrated unless otherwise instructed.,Report any hearing changes, ringing in ears, or numbness/tingling in hands or feet.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PARAPLATIN vs AURLUMYN, answered by our medical review team.
PARAPLATIN is a Antineoplastic Agent that works by Carboplatin, a platinum-based alkylating agent, forms interstrand and intrastrand DNA cross-links by binding to DNA guanine bases, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PARAPLATIN and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PARAPLATIN is: 360 mg/m2 IV every 3 weeks or area under the curve (AUC) 4-6 mg/m L/min IV every 3-4 weeks using Calvert formula.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PARAPLATIN and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PARAPLATIN is classified as Category C. Pregnancy Category D. First trimester: High risk of teratogenicity; embryotoxicity, fetal malformations (neural tube, skeletal, cardiovascular). Second and third trimesters: Risk o. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.